132 related articles for article (PubMed ID: 21276444)
1. Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.
Bolhassani A; Gholami E; Zahedifard F; Moradin N; Parsi P; Doustdari F; Seyed N; Papadopoulou B; Rafati S
Exp Parasitol; 2011 May; 128(1):9-17. PubMed ID: 21276444
[TBL] [Abstract][Full Text] [Related]
2. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread.
Perkins SD; Hartley MG; Lukaszewski RA; Phillpotts RJ; Stevenson FK; Bennett AM
Vaccine; 2005 Mar; 23(16):1931-40. PubMed ID: 15734065
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
5. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
Rafati S; Ghaemimanesh F; Zahedifard F
Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
[TBL] [Abstract][Full Text] [Related]
6. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
7. Intercellular trafficking of the major tegument protein VP22 of bovine herpesvirus-1 and its application to improve a DNA vaccine.
Zheng CF; Brownlie R; Huang DY; Babiuk LA; van Drunen Littel-van den Hurk S
Arch Virol; 2006 May; 151(5):985-93. PubMed ID: 16374718
[TBL] [Abstract][Full Text] [Related]
8. Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).
Yang SG; Wo JE; Li MW; Mi FF; Yu CB; Lv GL; Cao HC; Lu HF; Wang BH; Zhu H; Li LJ
Vaccine; 2009 Dec; 27(52):7451-8. PubMed ID: 19450640
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
10. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
11. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
[TBL] [Abstract][Full Text] [Related]
12. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus.
Saha S; Yoshida S; Ohba K; Matsui K; Matsuda T; Takeshita F; Umeda K; Tamura Y; Okuda K; Klinman D; Xin KQ; Okuda K
Virology; 2006 Oct; 354(1):48-57. PubMed ID: 16945400
[TBL] [Abstract][Full Text] [Related]
13. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
Gurunathan S; Prussin C; Sacks DL; Seder RA
Nat Med; 1998 Dec; 4(12):1409-15. PubMed ID: 9846579
[TBL] [Abstract][Full Text] [Related]
14. [Immunogenicity of DNA vaccine expressing GP5 of porcine reproductive and respiratory syndrome virus fused with VP22 of bovine herpesvirus 1].
Zhao W; Xiao SB; Fang LR; Jiang YB; Song YF; Yan L; Yu XL; Chen HC
Sheng Wu Gong Cheng Xue Bao; 2005 Sep; 21(5):725-30. PubMed ID: 16285512
[TBL] [Abstract][Full Text] [Related]
15. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines.
Carrión J; Folgueira C; Alonso C
Vaccine; 2008 Feb; 26(9):1155-65. PubMed ID: 18255202
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
17. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
Piedrafita D; Xu D; Hunter D; Harrison RA; Liew FY
J Immunol; 1999 Aug; 163(3):1467-72. PubMed ID: 10415048
[TBL] [Abstract][Full Text] [Related]
18. [Enhancement of cellular immune response to DNA vaccine encoding hepatitis C virus core and envelope 2 fusion antigen by murine Fms-like tyrosine kinase 3 ligand].
Ke JS; Zhao P; Cao J; Yu JP; Qi ZT
Sheng Wu Gong Cheng Xue Bao; 2003 Mar; 19(2):158-62. PubMed ID: 15966314
[TBL] [Abstract][Full Text] [Related]
19. A DNA vaccine encoding VP22 of herpes simplex virus type I (HSV-1) and OprF confers enhanced protection from Pseudomonas aeruginosa in mice.
Yu X; Wang Y; Xia Y; Zhang L; Yang Q; Lei J
Vaccine; 2016 Aug; 34(37):4399-405. PubMed ID: 27449680
[TBL] [Abstract][Full Text] [Related]
20. Effect of IL-22 on DNA vaccine encoding LACK gene of Leishmania major in BALB/c mice.
Hezarjaribi HZ; Ghaffarifar F; Dalimi A; Sharifi Z; Jorjani O
Exp Parasitol; 2013 Jul; 134(3):341-8. PubMed ID: 23541883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
